Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study
Background and Objective A new gastric cancer screening scoring system (NGCS) strategy was recommended for the early gastric cancer (GC) screening process in China. The current study aimed to assess the clinical benefits and the cost effectiveness of the NGCS strategy in GC high-risk areas of China from a societal perspective. Methods A Markov microsimulation model was developed to evaluate 30 alternative screening strategies with varying initiation age, including the NGCS strategy, the modified NGCS strategy, and the endoscopic screening strategy with various screening intervals. The primary outcomes included GC mortality, number of endoscopies, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Cost estimates were reported in 2021 USD (US$) and both costs and benefits were discounted at 5% annually. Deterministic and probabilistic sensitivity analyses were performed to evaluate model uncertainty. Results Screening with the NGCS strategy from age 40 years (40-NGCS) reduced the GC incidence by 86.4%, which provided the greatest benefit across strategies. Compared with all strategies, at a willingness-to pay threshold of US$17,922 per QALY, the 40-NGCS strategy was a leading cost-effective strategy, with an ICER of US$15,668 per QALY. Results were robust in univariate and probabilistic sensitivity analyses. The probability of the 40-NGCS strategy being cost effective was 0.863. Conclusions The 40-NGCS strategy was an effective and cost-effective strategy to reduce GC incidence and mortality in China. The findings provide important evidence for decision makers to formulate and optimize targeted approaches for GC prevention and control policies in China..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
PharmacoEconomics - 40(2022), 7 vom: 15. Juni, Seite 725-737 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qin, Shuxia [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 |
|---|
| doi: |
10.1007/s40273-022-01160-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079108263 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079108263 | ||
| 003 | DE-627 | ||
| 005 | 20230507081826.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40273-022-01160-8 |2 doi | |
| 035 | |a (DE-627)OLC2079108263 | ||
| 035 | |a (DE-He213)s40273-022-01160-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 330 |a 610 |q VZ |
| 082 | 0 | 4 | |a 070 |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Qin, Shuxia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 | ||
| 520 | |a Background and Objective A new gastric cancer screening scoring system (NGCS) strategy was recommended for the early gastric cancer (GC) screening process in China. The current study aimed to assess the clinical benefits and the cost effectiveness of the NGCS strategy in GC high-risk areas of China from a societal perspective. Methods A Markov microsimulation model was developed to evaluate 30 alternative screening strategies with varying initiation age, including the NGCS strategy, the modified NGCS strategy, and the endoscopic screening strategy with various screening intervals. The primary outcomes included GC mortality, number of endoscopies, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Cost estimates were reported in 2021 USD (US$) and both costs and benefits were discounted at 5% annually. Deterministic and probabilistic sensitivity analyses were performed to evaluate model uncertainty. Results Screening with the NGCS strategy from age 40 years (40-NGCS) reduced the GC incidence by 86.4%, which provided the greatest benefit across strategies. Compared with all strategies, at a willingness-to pay threshold of US$17,922 per QALY, the 40-NGCS strategy was a leading cost-effective strategy, with an ICER of US$15,668 per QALY. Results were robust in univariate and probabilistic sensitivity analyses. The probability of the 40-NGCS strategy being cost effective was 0.863. Conclusions The 40-NGCS strategy was an effective and cost-effective strategy to reduce GC incidence and mortality in China. The findings provide important evidence for decision makers to formulate and optimize targeted approaches for GC prevention and control policies in China. | ||
| 700 | 1 | |a Wang, Xuehong |4 aut | |
| 700 | 1 | |a Li, Sini |4 aut | |
| 700 | 1 | |a Tan, Chongqing |4 aut | |
| 700 | 1 | |a Zeng, Xiaohui |4 aut | |
| 700 | 1 | |a Luo, Xia |4 aut | |
| 700 | 1 | |a Yi, Lidan |4 aut | |
| 700 | 1 | |a Peng, Liubao |4 aut | |
| 700 | 1 | |a Wu, Meiyu |4 aut | |
| 700 | 1 | |a Peng, Ye |4 aut | |
| 700 | 1 | |a Wang, Liting |4 aut | |
| 700 | 1 | |a Wan, Xiaomin |0 (orcid)0000-0001-5315-8141 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d Springer International Publishing, 1992 |g 40(2022), 7 vom: 15. Juni, Seite 725-737 |w (DE-627)131043277 |w (DE-600)1100273-6 |w (DE-576)033026092 |x 1170-7690 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:7 |g day:15 |g month:06 |g pages:725-737 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s40273-022-01160-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 7 |b 15 |c 06 |h 725-737 | ||